Studies Further Demonstrate Clinical Utility & Cost-Effectiveness of bioTheranostics’ CancerTYPE ID® Molecular Test in Metastatic Cancer
Data released at 2013 ASCO meeting highlight impact of CancerTYPE ID on cancer management
FOR IMMEDIATE RELEASE…May 31, 2013…CHICAGO…bioTheranostics today announced that a number of studies on its CancerTYPE ID® molecular cancer classifier are being featured at the 2013 American Society of Clinical Oncology (ASCO) annual meeting. Findings from these studies add to the growing body of evidence supporting the clinical utility of CancerTYPE ID, demonstrating its impact on therapeutic decision making, cost-effectiveness and favorable quality of life, and particular utility in limited-tissue specimens. The studies are among 11 clinical trials and economic analyses released during the ASCO meeting that reinforce the clinical utility, prognostic performance, and cost-effectiveness of the company’s molecular diagnostic tests.
Key studies about CancerTYPE ID include:
“Clinicians are increasingly relying on CancerTYPE ID as a routine part of clinical practice when faced with difficult-to-diagnose metastatic cancers,” said Richard Ding, president and CEO of bioTheranostics. “We have published extensive clinical validation and patient outcome studies that lay the scientific foundation for CancerTYPE ID. These new cost-effectiveness and clinical utility studies have opened a new chapter for our innovative products. Collectively, the clinical evidence supports a broad and standard application of CancerTYPE ID in metastatic cancer management.”
Abstracts for the 11 ASCO studies concerning bioTheranostics’ molecular tests can be accessed on the ASCO website.
bioTheranostics is the leading solution provider for metastatic cancer management, leveraging its unique expertise in expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAP-accredited diagnostic laboratory to perform its proprietary tests: the CancerTYPE ID® molecular classification test; PRÉCIS® Precision Medicine, which includes biomarker profiles for non-small cell lung and colorectal cancers, and other cancers; and
Breast Cancer IndexSM, which quantifies risk of recurrence of estrogen receptor-positive, lymph node-negative breast cancer. bioTheranostics, a bioMérieux company, is based in San Diego. For more information, visit www.biotheranostics.com.